Log In
BCIQ
Print this Print this
 

SuliXen

  Manage Alerts
Collapse Summary General Information
Company Xenetic Biosciences Inc.
DescriptionLong-acting insulin formulated using polysialic acid
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationDiabetes
Indication DetailsTreat Type I and Type II diabetes
Regulatory Designation
PartnerPharmsynthez JSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/23/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today